// App-Quantinova.ai

POS1048 (2021) : IN PHASE-3 TRIALS DISCOVER 1 & 2, GUSELKUMAB REDUCED FATIGUE OVER 52 WEEKS IN PATIENTS WITH PSORIATIC ARTHRITIS AND DEMONSTRATED INDEPENDENT TREATMENT EFFECTS ON FATIGUE AFTER ADJUSTMENT FOR CLINICAL RESPONSE (ACR20)

Researchers

Presenter

  • P. Rahman

Principal Investigators

  • P. Helliwell

  • A. Deodhar

  • A. Kollmeier

  • E. C. Hsia

  • B. Zhou

  • X. Lin

  • C. Han

  • P. J. Mease

Medical Centers

  • Memorial University of Newfoundland, Disicpline of Medicine, Faculty of Medicine, St. Johns, Canada

  • University of Leeds, Rheumatology, Leeds, United Kingdom

  • Oregon Health & Science University, Division of Arthritis & Rheumatic Diseases, Oregon, United States of America

  • Janssen Research & Development, Raritan, United States of America

  • University of Pennsylvania, School of Veterinary Medicine, Section of Cardiology, Philadelphia, United States of America

  • Janssen Research & Development, Raritan, United States of America

  • Janssen Research & Development, Raritan, United States of America

  • Janssen Research & Development, Raritan, United States of America

  • Swedish Medical Center/Providence St. Joseph Health and University of Washington School of Medicine, Rheumatology Research, Seattle, United States of America

Locations

  • Canada

  • United Kingdom

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Musculoskeletal

  • Dermatology

Disease

  • Psoriatic arthritis

Biomarkers

  • N/A

Drug/Treatment

  • guselkumab (IV)

Outcome

  • N/A

Study Design

  • Randomized

  • Double Blind/Blinded

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved